Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2022

01-04-2022 | Metastasis | Guidelines

EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

Authors: M. Weber, M. Lam, C. Chiesa, M. Konijnenberg, M. Cremonesi, P. Flamen, S. Gnesin, L. Bodei, T. Kracmerova, M. Luster, E. Garin, K. Herrmann

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2022

Login to get access

Abstract

Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10–20% of patients are amenable to curative treatment, such as resection or transplant. Liver metastases are most frequently caused by colorectal cancer, which accounts for the second most cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown to be a safe and effective treatment option. The vast potential of personalized dosimetry has also been shown, resulting in markedly increased response rates and overall survival. In a rapidly evolving therapeutic landscape, the role of radioembolization will be subject to changes. Therefore, the decision for radioembolization should be taken by a multidisciplinary tumour board in accordance with the current clinical guidelines. The purpose of this procedure guideline is to assist the nuclear medicine physician in treating and managing patients undergoing radioembolization treatment.

Preamble

The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set out in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine involves not only the science but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognised that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.
Footnotes
1
99mTc-labelled human serum albumin (HSA) particles are not widely available but can also be used.
 
2
Planar and, possibly, single-photon emission computed tomography with integrated computed tomography (SPECT/CT)
 
3
Oral administration of sodium perchlorate before the MAA injection can be considered to prevent physiological uptake of free 99mTc-pertechnetate in the stomach that can be mistaken for visceral shunting.
 
Literature
1.
go back to reference Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.PubMed Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.PubMed
2.
go back to reference Salem R, Thurston KG. Radioembolization with (90)yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251–78.PubMedCrossRef Salem R, Thurston KG. Radioembolization with (90)yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251–78.PubMedCrossRef
3.
go back to reference Smits MLJ, et al., Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental & Clinical Cancer Research, 2010. 29. Smits MLJ, et al., Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental & Clinical Cancer Research, 2010. 29.
4.
go back to reference Westcott MA, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351–64.PubMedPubMedCentralCrossRef Westcott MA, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351–64.PubMedPubMedCentralCrossRef
6.
go back to reference Lau WY, Li AK. Therapeutic aspects of radioisotopes in hepatobiliary malignancy. Br J Surg. 1992;79(7):711.PubMedCrossRef Lau WY, Li AK. Therapeutic aspects of radioisotopes in hepatobiliary malignancy. Br J Surg. 1992;79(7):711.PubMedCrossRef
7.
go back to reference Okuda K, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–28.PubMedCrossRef Okuda K, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–28.PubMedCrossRef
9.
go back to reference Lambert B, et al. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328–33.PubMedCrossRef Lambert B, et al. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328–33.PubMedCrossRef
10.
go back to reference Leung WT, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35(1):70–3.PubMed Leung WT, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35(1):70–3.PubMed
11.
go back to reference Braat A, et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920–8.PubMedCrossRef Braat A, et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920–8.PubMedCrossRef
12.
go back to reference Elschot M, et al. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75.PubMedCrossRef Elschot M, et al. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75.PubMedCrossRef
13.
go back to reference Dancey JE, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673–81.PubMed Dancey JE, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673–81.PubMed
14.
go back to reference Geschwind JF, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194–205.PubMedCrossRef Geschwind JF, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194–205.PubMedCrossRef
15.
go back to reference Goin JE, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195–203.PubMedCrossRef Goin JE, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195–203.PubMedCrossRef
16.
go back to reference Kennedy AS, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.PubMedCrossRef Kennedy AS, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.PubMedCrossRef
17.
go back to reference Lau WY, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40(3):583–92.PubMedCrossRef Lau WY, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40(3):583–92.PubMedCrossRef
18.
go back to reference Sharma RA, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106.PubMedCrossRef Sharma RA, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106.PubMedCrossRef
19.
go back to reference Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294–302.PubMedCrossRef Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294–302.PubMedCrossRef
20.
go back to reference Hogberg J, et al. Increased absorbed liver dose in selective internal radiation therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2(1):10.PubMedPubMedCentralCrossRef Hogberg J, et al. Increased absorbed liver dose in selective internal radiation therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2(1):10.PubMedPubMedCentralCrossRef
21.
go back to reference Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl 1):S107–10.PubMedCrossRef Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl 1):S107–10.PubMedCrossRef
22.
go back to reference Garin E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010;37(3):453–61.PubMedCrossRef Garin E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010;37(3):453–61.PubMedCrossRef
23.
go back to reference Sangro B, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792–800.PubMedCrossRef Sangro B, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792–800.PubMedCrossRef
24.
go back to reference Van Hazel G, et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.PubMedCrossRef Van Hazel G, et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.PubMedCrossRef
25.
go back to reference Lam MG, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(2):323–9.PubMedCrossRef Lam MG, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(2):323–9.PubMedCrossRef
26.
go back to reference Young JY, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(11):1375–82.PubMedCrossRef Young JY, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(11):1375–82.PubMedCrossRef
27.
go back to reference Ezziddin S, et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663–9.PubMedCrossRef Ezziddin S, et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663–9.PubMedCrossRef
28.
go back to reference Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43(2):246–53.PubMedCrossRef Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43(2):246–53.PubMedCrossRef
29.
go back to reference Sangro B, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–46.PubMedCrossRef Sangro B, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–46.PubMedCrossRef
30.
go back to reference van Hazel GA, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.PubMedCrossRef van Hazel GA, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.PubMedCrossRef
31.
go back to reference Mulcahy, M.F., et al., Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol, 2021: p. JCO2101839. Mulcahy, M.F., et al., Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol, 2021: p. JCO2101839.
32.
go back to reference Wasan HS, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.PubMedPubMedCentralCrossRef Wasan HS, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.PubMedPubMedCentralCrossRef
33.
go back to reference Ricke J, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74.PubMedCrossRef Ricke J, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74.PubMedCrossRef
34.
go back to reference Edeline, J., et al., Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol, 2019. Edeline, J., et al., Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol, 2019.
35.
go back to reference Shady W, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: a comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016;85(6):1224–31.PubMedPubMedCentralCrossRef Shady W, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: a comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016;85(6):1224–31.PubMedPubMedCentralCrossRef
36.
go back to reference Shady W, et al. Surrogate imaging biomarkers of response of colorectal liver metastases after salvage radioembolization using 90Y-loaded resin microspheres. AJR Am J Roentgenol. 2016;207(3):661–70.PubMedPubMedCentralCrossRef Shady W, et al. Surrogate imaging biomarkers of response of colorectal liver metastases after salvage radioembolization using 90Y-loaded resin microspheres. AJR Am J Roentgenol. 2016;207(3):661–70.PubMedPubMedCentralCrossRef
37.
go back to reference Fendler WP, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54(8):1202–8.PubMedCrossRef Fendler WP, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54(8):1202–8.PubMedCrossRef
38.
go back to reference Gulec SA, et al. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38(7):1289–95.PubMedCrossRef Gulec SA, et al. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38(7):1289–95.PubMedCrossRef
39.
go back to reference Soydal C, et al. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34(5):501–6.PubMedCrossRef Soydal C, et al. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34(5):501–6.PubMedCrossRef
40.
go back to reference Zerizer I, et al. The role of early (1)(8)F-FDG PET/CT in prediction of progression-free survival after (9)(0)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39(9):1391–9.PubMedCrossRef Zerizer I, et al. The role of early (1)(8)F-FDG PET/CT in prediction of progression-free survival after (9)(0)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39(9):1391–9.PubMedCrossRef
42.
go back to reference Vilgrain V, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.PubMedCrossRef Vilgrain V, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.PubMedCrossRef
43.
go back to reference Dutton SJ, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.PubMedPubMedCentralCrossRef Dutton SJ, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.PubMedPubMedCentralCrossRef
44.
go back to reference Gray B, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.PubMedCrossRef Gray B, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.PubMedCrossRef
45.
go back to reference Chow PKH, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.PubMedCrossRef Chow PKH, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.PubMedCrossRef
46.
go back to reference Helmberger T, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35.PubMedCrossRef Helmberger T, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35.PubMedCrossRef
47.
go back to reference Schutte K, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer. 2020;9(6):771–86.PubMedPubMedCentralCrossRef Schutte K, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer. 2020;9(6):771–86.PubMedPubMedCentralCrossRef
48.
go back to reference Kohler M, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9:1.CrossRef Kohler M, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9:1.CrossRef
49.
go back to reference Hunt AP, et al. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur J Pharm Biopharm. 2006;62(1):26–31.PubMedCrossRef Hunt AP, et al. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur J Pharm Biopharm. 2006;62(1):26–31.PubMedCrossRef
50.
go back to reference Chiesa C, Maccauro M. (166)Ho microsphere scout dose for more accurate radioembolization treatment planning. Eur J Nucl Med Mol Imaging. 2020;47(4):744–7.PubMedCrossRef Chiesa C, Maccauro M. (166)Ho microsphere scout dose for more accurate radioembolization treatment planning. Eur J Nucl Med Mol Imaging. 2020;47(4):744–7.PubMedCrossRef
51.
go back to reference Grosser OS, et al. Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry: influence on the liver-lung shunt. J Nucl Med. 2016;57(6):925–7.PubMedCrossRef Grosser OS, et al. Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry: influence on the liver-lung shunt. J Nucl Med. 2016;57(6):925–7.PubMedCrossRef
52.
go back to reference Lopez B, et al. Calculation of lung mean dose and quantification of error for (90) Y-microsphere radioembolization using (99m) Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys. 2019;46(9):3929–40.PubMedCrossRef Lopez B, et al. Calculation of lung mean dose and quantification of error for (90) Y-microsphere radioembolization using (99m) Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys. 2019;46(9):3929–40.PubMedCrossRef
53.
go back to reference Das A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020;47(4):807–15.PubMedCrossRef Das A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020;47(4):807–15.PubMedCrossRef
54.
go back to reference Ho S, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–8.PubMed Ho S, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–8.PubMed
55.
go back to reference Salem R, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431–8.PubMedCrossRef Salem R, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431–8.PubMedCrossRef
56.
go back to reference Jadoul A, et al. Comparative dosimetry between (99m)Tc-MAA SPECT/CT and (90)Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):828–37.PubMedCrossRef Jadoul A, et al. Comparative dosimetry between (99m)Tc-MAA SPECT/CT and (90)Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):828–37.PubMedCrossRef
57.
go back to reference Gnesin S, et al. Partition model based Tc-99m-MAA SPECT/CT predictive dosimetry compared with Y-90 TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672–8.PubMedCrossRef Gnesin S, et al. Partition model based Tc-99m-MAA SPECT/CT predictive dosimetry compared with Y-90 TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672–8.PubMedCrossRef
58.
go back to reference Ilhan H, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56(11):1654–60.PubMedCrossRef Ilhan H, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56(11):1654–60.PubMedCrossRef
59.
go back to reference Wondergem M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294–301.PubMedCrossRef Wondergem M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294–301.PubMedCrossRef
60.
go back to reference Haste P, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission ct and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28(5):722–30.PubMedCrossRef Haste P, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission ct and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28(5):722–30.PubMedCrossRef
61.
go back to reference Garin E, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.PubMedPubMedCentralCrossRef Garin E, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.PubMedPubMedCentralCrossRef
62.
go back to reference Garin E, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.PubMedCrossRef Garin E, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.PubMedCrossRef
63.
go back to reference Chiesa C, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55(2):168–97.PubMed Chiesa C, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55(2):168–97.PubMed
64.
go back to reference Ho CL, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45(12):2110–21.PubMedCrossRef Ho CL, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45(12):2110–21.PubMedCrossRef
65.
go back to reference Hermann AL, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673–84.PubMedCrossRef Hermann AL, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673–84.PubMedCrossRef
66.
go back to reference Lau WY, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70(5):994–9.PubMedPubMedCentralCrossRef Lau WY, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70(5):994–9.PubMedPubMedCentralCrossRef
67.
go back to reference Garin, E., et al., Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol, 2020 Garin, E., et al., Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol, 2020
68.
go back to reference Smits MLJ, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806.PubMedCrossRef Smits MLJ, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806.PubMedCrossRef
69.
go back to reference Salem R, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.PubMedCrossRef Salem R, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.PubMedCrossRef
70.
go back to reference Lewandowski RJ, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–8.PubMedCrossRef Lewandowski RJ, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–8.PubMedCrossRef
71.
go back to reference Meiers C, et al. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol. 2018;9(2):311–5.PubMedPubMedCentralCrossRef Meiers C, et al. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol. 2018;9(2):311–5.PubMedPubMedCentralCrossRef
72.
go back to reference Padia SA, et al. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73.PubMedCrossRef Padia SA, et al. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73.PubMedCrossRef
73.
go back to reference Biederman DM, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30–7 e2.PubMedCrossRef Biederman DM, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30–7 e2.PubMedCrossRef
74.
go back to reference Garin E, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.PubMedCrossRef Garin E, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.PubMedCrossRef
75.
go back to reference Konijnenberg M., et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021:48(1);67–72 Konijnenberg M., et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021:48(1);67–72
76.
go back to reference Ho S, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947–52 Ho S, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947–52
77.
go back to reference Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718–38.PubMedCrossRef Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718–38.PubMedCrossRef
78.
go back to reference Chiesa C, Bardies M, Zaidi H. Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy. Med Phys. 2019;46(12):5403–6.PubMedCrossRef Chiesa C, Bardies M, Zaidi H. Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy. Med Phys. 2019;46(12):5403–6.PubMedCrossRef
79.
go back to reference Dewaraja YK, et al. Prediction of tumor control in (90)Y radioembolization by logit models with PET/CT-based dose metrics. J Nucl Med. 2020;61(1):104–11.PubMedPubMedCentralCrossRef Dewaraja YK, et al. Prediction of tumor control in (90)Y radioembolization by logit models with PET/CT-based dose metrics. J Nucl Med. 2020;61(1):104–11.PubMedPubMedCentralCrossRef
80.
go back to reference Kappadath SC, et al. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451–61.PubMedCrossRef Kappadath SC, et al. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451–61.PubMedCrossRef
81.
go back to reference Chiesa, C., et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre- and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021:8(1);77 Chiesa, C., et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre- and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021:8(1);77
82.
go back to reference Roosen, J., et al., To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging, 2021. Roosen, J., et al., To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging, 2021.
83.
go back to reference Salem R, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021. Salem R, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021.
84.
go back to reference Lewandowski RJ, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99–105.PubMedCrossRef Lewandowski RJ, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99–105.PubMedCrossRef
85.
go back to reference Palard X, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392–401.PubMedCrossRef Palard X, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392–401.PubMedCrossRef
86.
go back to reference Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018–32.PubMedCrossRef Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018–32.PubMedCrossRef
87.
go back to reference Shepherd FA, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70(9):2250–4.PubMedCrossRef Shepherd FA, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70(9):2250–4.PubMedCrossRef
88.
go back to reference Bourien H, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46(3):669–76.PubMedCrossRef Bourien H, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46(3):669–76.PubMedCrossRef
89.
go back to reference Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.PubMedPubMedCentralCrossRef Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.PubMedPubMedCentralCrossRef
90.
go back to reference Padia SA, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172–8.PubMedCrossRef Padia SA, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172–8.PubMedCrossRef
91.
go back to reference Alsultan, A.A., et al., Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases. J Nucl Med, 2021. Alsultan, A.A., et al., Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases. J Nucl Med, 2021.
92.
go back to reference Lewandowski RJ, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1861–9.PubMedCrossRef Lewandowski RJ, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1861–9.PubMedCrossRef
93.
go back to reference Levillain, H., et al., International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging, 2021 Levillain, H., et al., International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging, 2021
94.
go back to reference Levillain H, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–9.PubMedCrossRef Levillain H, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–9.PubMedCrossRef
95.
go back to reference van den Hoven AF, et al. Insights into the dose-response relationship of radioembolization with resin 90y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9.PubMedCrossRef van den Hoven AF, et al. Insights into the dose-response relationship of radioembolization with resin 90y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9.PubMedCrossRef
96.
go back to reference Bastiaannet R, et al. First evidence for a dose-response relationship in patients treated with (166)Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608–12.PubMedCrossRef Bastiaannet R, et al. First evidence for a dose-response relationship in patients treated with (166)Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608–12.PubMedCrossRef
97.
go back to reference van Roekel C, et al. Dose-effect relationships of (166)Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272–9.PubMedCrossRef van Roekel C, et al. Dose-effect relationships of (166)Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272–9.PubMedCrossRef
98.
go back to reference Vauthey JN, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233–40.PubMedCrossRef Vauthey JN, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233–40.PubMedCrossRef
99.
go back to reference Ahmadzadehfar H, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. EJNMMI Res. 2015;5(1):54.PubMedPubMedCentralCrossRef Ahmadzadehfar H, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. EJNMMI Res. 2015;5(1):54.PubMedPubMedCentralCrossRef
100.
go back to reference Giammarile F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–406.PubMedCrossRef Giammarile F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–406.PubMedCrossRef
101.
go back to reference Lhommel R, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37(9):1654–62.PubMedCrossRef Lhommel R, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37(9):1654–62.PubMedCrossRef
102.
go back to reference Selwyn RG, et al. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot. 2007;65(3):318–27.PubMedCrossRef Selwyn RG, et al. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot. 2007;65(3):318–27.PubMedCrossRef
103.
go back to reference Kesim S, et al. Unexpected radiation pneumonitis after SIRT with significant decrease in DLCO with internal radiation exposure: a case report. BMC Med Imaging. 2020;20(1):52.PubMedPubMedCentralCrossRef Kesim S, et al. Unexpected radiation pneumonitis after SIRT with significant decrease in DLCO with internal radiation exposure: a case report. BMC Med Imaging. 2020;20(1):52.PubMedPubMedCentralCrossRef
104.
go back to reference Auditore L, et al. Monte Carlo (90)Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol. 2020;65(23):235014.PubMedCrossRef Auditore L, et al. Monte Carlo (90)Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol. 2020;65(23):235014.PubMedCrossRef
105.
go back to reference Scott NP, McGowan DR. Optimising quantitative (90)Y PET imaging: an investigation into the effects of scan length and Bayesian penalised likelihood reconstruction. EJNMMI Res. 2019;9(1):40.PubMedPubMedCentralCrossRef Scott NP, McGowan DR. Optimising quantitative (90)Y PET imaging: an investigation into the effects of scan length and Bayesian penalised likelihood reconstruction. EJNMMI Res. 2019;9(1):40.PubMedPubMedCentralCrossRef
106.
go back to reference Elschot M, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.PubMedPubMedCentralCrossRef Elschot M, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.PubMedPubMedCentralCrossRef
107.
go back to reference van de Maat GH, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23(3):827–35.PubMedCrossRef van de Maat GH, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23(3):827–35.PubMedCrossRef
108.
go back to reference John, L., Discharge of patients undergoing treatment with radioactive substances, A.R.P.a.N.S. Agency, Editor. 2002: Australia John, L., Discharge of patients undergoing treatment with radioactive substances, A.R.P.a.N.S. Agency, Editor. 2002: Australia
109.
go back to reference Prince JF, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol. 2014;25(12):1956–1963e1.PubMedCrossRef Prince JF, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol. 2014;25(12):1956–1963e1.PubMedCrossRef
110.
go back to reference Laffont S, et al. Occupational radiation exposure of medical staff performing (9)(0)Y-loaded microsphere radioembolization. Eur J Nucl Med Mol Imaging. 2016;43(5):824–31.PubMedCrossRef Laffont S, et al. Occupational radiation exposure of medical staff performing (9)(0)Y-loaded microsphere radioembolization. Eur J Nucl Med Mol Imaging. 2016;43(5):824–31.PubMedCrossRef
111.
go back to reference Taleb J, et al. Radiation dose measurements for staff members involved in holmium-166 preclinical trial. Radiat Meas. 2013;58:75–8.CrossRef Taleb J, et al. Radiation dose measurements for staff members involved in holmium-166 preclinical trial. Radiat Meas. 2013;58:75–8.CrossRef
112.
go back to reference Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209–11.PubMed Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209–11.PubMed
113.
go back to reference Metyko J, et al. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management. Health Phys. 2012;103(5 Suppl 3):S204–8.PubMedCrossRef Metyko J, et al. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management. Health Phys. 2012;103(5 Suppl 3):S204–8.PubMedCrossRef
114.
go back to reference Elsayed M, et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med. 2020;45(2):100–4.PubMedCrossRef Elsayed M, et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med. 2020;45(2):100–4.PubMedCrossRef
115.
go back to reference Lam MG, et al. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36(5):1320–8.PubMedCrossRef Lam MG, et al. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36(5):1320–8.PubMedCrossRef
117.
go back to reference Zarva A, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55(3):360–6.PubMedCrossRef Zarva A, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55(3):360–6.PubMedCrossRef
118.
go back to reference Prajapati HJ, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965–73.PubMedCrossRef Prajapati HJ, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965–73.PubMedCrossRef
119.
go back to reference Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.PubMedCrossRef Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.PubMedCrossRef
120.
go back to reference Shim JH, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262(2):708–18.PubMedCrossRef Shim JH, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262(2):708–18.PubMedCrossRef
121.
go back to reference Gillmore R, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.PubMedCrossRef Gillmore R, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.PubMedCrossRef
122.
go back to reference European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182–236 European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182–236
123.
go back to reference Pollock RF, et al. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020;20(11):997–1009.PubMedCrossRef Pollock RF, et al. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020;20(11):997–1009.PubMedCrossRef
124.
go back to reference Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413–25.PubMedCrossRef Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413–25.PubMedCrossRef
125.
go back to reference Memon K, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887–94.PubMedCrossRef Memon K, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887–94.PubMedCrossRef
126.
go back to reference Beuzit L, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85(8):1445–52.PubMedCrossRef Beuzit L, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85(8):1445–52.PubMedCrossRef
127.
go back to reference Camacho JC, et al. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.PubMedCrossRef Camacho JC, et al. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.PubMedCrossRef
128.
go back to reference Akinwande O, et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol. 2016;113(4):443–8.PubMedCrossRef Akinwande O, et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol. 2016;113(4):443–8.PubMedCrossRef
Metadata
Title
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds
Authors
M. Weber
M. Lam
C. Chiesa
M. Konijnenberg
M. Cremonesi
P. Flamen
S. Gnesin
L. Bodei
T. Kracmerova
M. Luster
E. Garin
K. Herrmann
Publication date
01-04-2022
Publisher
Springer Berlin Heidelberg
Keyword
Metastasis
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-021-05600-z

Other articles of this Issue 5/2022

European Journal of Nuclear Medicine and Molecular Imaging 5/2022 Go to the issue